About us

Triphase Accelerator acquires promising cancer therapies and accelerates their development from pre-IND to clinical proof-of-concept leveraging our deep relationships with world-class scientists, clinicians and business professionals with access to state-of-the-art facilities and capabilities.

Our expertise is concentrated on developing innovative high-value potential drug candidates that have the promise to be transformative to patients, determining whether they should be advanced through further development, and efficiently executing that advancement in a timely and cost-effective manner.

news and events

Triphase Accelerator Announces New Collaboration with Celgene Corporation for TRPH-222, an anti-CD22 Antibody Drug Conjugate

Find out More

Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant …

Find out More

Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation

Find out More

Catalent Biologics And Triphase Accelerator Corportion Announce License Agreement To Advance SMARTagTM ADC To Clinic

Find out More

partner with us

Triphase Accelerator seeks to develop relationships with companies and research institutions looking to advance oncology drug candidates with substantial, but unrealized medical and commercial value. Triphase specializes in efficient and cost-effective drug development and can help realize the potential of these compounds.